41
Participants
Start Date
October 27, 2010
Primary Completion Date
May 1, 2015
Study Completion Date
May 1, 2015
SPD422 (anagrelide hydrochloride)
Subjects will be continued on the dose of anagrelide that controlled their platelet levels in Study 308 and titrated if necessary.
Akita University Hospital, Akita
Tokyo Metropolitan Cancer and Infectious diseases Center Kom, Honkomagome 3-18-22
Nippon Medical School Hospital, Sendagi 1-1-5
Chiba University Hospital, Chuo-ku Inohana 1-8-1
Hokkaido University Hospital, Sapporo
Tokai University Hospital, Isehara-shi
Gunma University Hospital, Showa-machi 3-39-15
NHO Tokyo Medical Center, Higashigaoka 2-5-1
Mie University Hospital, Tsu
University of Miyazaki Hospital, Miyazaki
Niigata Cancer Centre, Niigata
Okayama University Hospital, Okayama
Osaka City University Hospital, Osaka
Osaka University Hospital, Suita-shi
Juntendo University Shizuoka Hospital, Izunokuni-shi
Keio University Hospital, Tokyo
Lead Sponsor
Shire
INDUSTRY